Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst
Japanese drug major Eisai (TYO: 4523) has announced the first European launch today of Fycompa (perampanel), the first in an entirely new class of treatment for uncontrolled partial epilepsy (the most common form of the condition), in the UK.
The new therapy, which was approved for marketing earlier this year by the European Commission (The Pharma Letter July 30), has demonstrated efficacy in partial onset seizures, in particular with secondary generalizations. It is indicated as an adjunctive treatment for partial-onset seizures, with or without secondarily generalized seizures, in people with epilepsy aged 12 years and older.
The worldwide supply of this new drug will be manufactured, packaged and distributed from the company’s new £100 million ($159 million) facility in Hatfield, Hertfordshire, UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze